Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: JSC Pharmasyntez
Street 1: Presnenskay emb., 12
Street 2:
City: Moscow
Province:
Post Code: 123100
Country: Russian Federation
Phone: +7 495 750 5437
Organization Email: moscow@pharmasyntez.com
Web Site: http://www.pharmasyntez.com
Other Online Presence:

Focal Point Contact Information

Salutation: Dr.
First Name: Sergey
Last Name: Koren
Title: MD, PhD
Email: president@pharmasyntez.com
Phone: +7 925 544 7324

Alternate Focal Point Contact Information

Salutation: Mr.
First Name: Vikram
Last Name: Punia
Title:  
Email: president@pharmasyntez.com
Phone:  

General Information

Board Constituency: Private sector
Is your organization legally registered in your country: Yes
If yes, please enter your registration number:
Organization Type - Primary: Private Sector
Organization Type - Secondary: Company
Organization Description:
JSC “Pharmasyntez” mission is to produce the latest pharmaceutical products of the highest quality that is available to patients, healthcare administrations and our partners. We are committed in the development and productions of innovative drugs. We are the only Russian Pharmaceutical company to develop a New Chemical Entity (NCE) “PERHLOZONE” for the treatment of Multi-Drug Resistant Tuberculosis (MDRTB). Our primary focus is to develop and manufacture innovative pharmaceuticals for the treatment of diseases which are socially significant like Anti-TB, Oncology, ARV’s and immune-modulators. Overall the primary mission of the company is to “Develop and manufacture innovative quality pharmaceuticals with a social responsibility”
 
Do you know about the UNHLM declaration:

Specializations / Areas of Work

Provision of drugs, diagnostics and commodities
Research and Development

Other Organization Information

Total number of staff in your organization: 100 +
Number of full-time staff who are directly involved with TB: 100 +
Number of part-time staff who are directly involved with TB: 100 +
Number of volunteers who are directly involved with TB: 1 - 5
 
How did you hear about the Stop TB Partnership: Internet search
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Network with other partners
 
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: No
Please tell us how your organization is contributing to your country's national TB control plan:
AntiTB drugs production and distribution
 

Geographical Reach

Which country is your headquarters located in: Russian Federation
Which countries do you do operate in:
(This includes countries you are conducting activities in)
Eswatini
India
Indonesia
Iran (Islamic Republic of)
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Lithuania
Luxembourg
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Mexico
Micronesia (Federated States of)
Monaco
Mongolia
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Qatar
Republic of Korea
Republic of Moldova
Republic of Montenegro
Republic of Serbia
Romania
Russian Federation
Rwanda
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Sweden
Switzerland
Syrian Arab Republic
Tajikistan
Thailand
The Former Yugoslav Rep of Macedonia
Togo
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom of Great Britain and Northern Ireland
United Republic of Tanzania
United States of America
Uruguay

Contribution

Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

Drug-Resistant TB:
Has conducted 3 Phase clinical trials on novel anti MDR TB drug Perchlozone.

TB-HIV:
Will continue clinical studies on novel antiTB drugs in HIV positive patients (safety and including drug to drug interactions)

Laboratory Strengthening:
Has own laboratory

New TB Drugs:
Has Phase 3 finished novel antiTB and anti MDR TB drug Perchlozone
Have several new substances to be studied

Fundamental Research:
Searching for new antiTB drugs and moleculs

Research:
New treatment regimen development

Declaration

Declaration of interests:
No conflicts of interest were delacred.

Application date: July 9, 2012
Last updated: January 24, 2017